Medicus Pharma Shares Set to Reverse Split on Monday, October 12th (NASDAQ:MDCX)

Medicus Pharma Ltd (NASDAQ:MDCX – Free Report)’s stock is set to reverse split on the morning of Monday, October 12th. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 11th.

Medicus Pharma Price Performance

Shares of MDCX stock traded down $0.06 on Thursday, reaching $0.10. 14,223,635 shares of the company were exchanged, compared to its average volume of 4,184,012. Medicus Pharma has a one year low of $0.09 and a one year high of $2.78. The company has a market cap of $6.44 million, a price-to-earnings ratio of -0.04 and a beta of 0.30. The company has a 50-day moving average of $0.22 and a 200-day moving average of $0.32.

Get Medicus Pharma alerts:

Medicus Pharma (NASDAQ:MDCX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). As a group, sell-side analysts predict that Medicus Pharma will post -0.73 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, October 2nd. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Check Out Our Latest Stock Report on MDCX

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Medicus Pharma stock. Sterling Investment Advisors Ltd. acquired a new stake in Medicus Pharma Ltd (NASDAQ:MDCX – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 100,000 shares of the company’s stock, valued at approximately $45,000. Sterling Investment Advisors Ltd. owned 0.16% of Medicus Pharma as of its most recent filing with the SEC.

Medicus Pharma Company Profile

(Get Free Report)

Medicus Pharma Ltd. is a life sciences company focused on acquiring, developing and commercializing innovative therapeutic and medical device technologies. Its activities are centered primarily on wound care, dermatology and related areas of medical treatment.

The company’s portfolio includes Natrox® Oxygen Wound Therapy, a device designed to deliver continuous topical oxygen to the wound site. The technology is intended to support the treatment of chronic and hard-to-heal wounds and may be used in clinical and home-care settings, subject to applicable regulatory approvals.

Medicus Pharma serves healthcare markets through the commercialization of its technologies and partnerships with medical professionals and distribution networks.

See Also

• Five stocks we like better than Medicus Pharma
• Want Private-Market Access to Kalshi and Polymarket? Try This ETF
• Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
• PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
• Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push

Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.